Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
Authors
Keywords
-
Journal
Breast Cancer
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-26
DOI
10.1007/s12282-023-01511-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
- (2023) Jiao Yang et al. BMC CANCER
- What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?
- (2023) Dario Trapani et al. CANCER
- Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study
- (2023) Ravi K. Goyal et al. CANCER
- Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.
- (2023) Takahiro Kogawa et al. JOURNAL OF CLINICAL ONCOLOGY
- VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, Biomarker Results
- (2022) Geoffrey J. Lindeman et al. CLINICAL CANCER RESEARCH
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
- (2022) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
- (2022) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- (2022) Francois-Clement Bidard et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions
- (2022) Felice Musicco et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Global Burden of Female Breast Cancer: Age-Period-Cohort Analysis of Incidence Trends From 1990 to 2019 and Forecasts for 2035
- (2022) Yizhen Li et al. Frontiers in Oncology
- Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
- (2022) Zhou Zhu et al. npj Precision Oncology
- LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
- (2022) M.P. Goetz et al. ANNALS OF ONCOLOGY
- Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
- (2022) Hope S. Rugo et al. npj Breast Cancer
- CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies
- (2021) Nadia Harbeck et al. Future Oncology
- Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA ‐3
- (2021) Hope S. Rugo et al. ONCOLOGIST
- The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
- (2020) Tatsunori Shimoi et al. Breast Cancer
- Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
- (2020) Masato Takahashi et al. Cancer Medicine
- Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
- (2020) Richard S. Finn et al. BREAST CANCER RESEARCH AND TREATMENT
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
- (2019) H. S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- Real-world data: towards achieving the achievable in cancer care
- (2019) Christopher M. Booth et al. Nature Reviews Clinical Oncology
- Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer
- (2019) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study
- (2018) Norikazu Masuda et al. CANCER SCIENCE
- Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
- (2018) Hirofumi Mukai et al. International Journal of Clinical Oncology
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Ann H. Partridge et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search